Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.64 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.60 |
| ▸ | KDR | P35968 | 1/20 | 0.59 |
| ▸ | CDK8 | P49336 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | RAF1 | P04049 | 2/20 | 0.57 |
| ▸ | BRAF | P15056 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | MLYCD | O95822 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14192701 | 0.91 | CDK8 (0.69) | MAPTLMNAKCNJ5KCNJ3POLB | |
| SCHEMBL3544292 | 0.89 | LMNA (0.65) | MAPTLMNAKCNJ5KCNJ3POLB | |
| SCHEMBL3544378 | 0.88 | LMNA (0.62) | MAPTLMNAKCNJ5KCNJ3POLB | |
| SCHEMBL14192702 | 0.87 | MAPT (0.61) | MAPTLMNAKCNJ5KCNJ3POLB | |
| SCHEMBL19966905 | 0.87 | MAPT (0.61) | MAPTLMNAKCNJ5KCNJ3POLB | |
| SCHEMBL3549181 | 0.84 | LMNA (0.63) | MAPTLMNAKCNJ5KCNJ3POLB | |
| SCHEMBL3544690 | 0.83 | RAF1 (0.61) | MAPTLMNAKCNJ5KCNJ3POLB | |
| SCHEMBL26546756 | 0.82 | KDR (0.76) | MAPTLMNAKCNJ5KCNJ3POLB | |
| SCHEMBL3542181 | 0.81 | HDAC3 (0.58) | MAPTLMNAKCNJ5KCNJ3POLB | |
| SCHEMBL13547754 | 0.81 | RAF1 (0.66) | MAPTLMNASMN1; SMN2GAATRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008354-B2 | TNF-family death receptor ligand-resistant cells to one or more TNF-family death receptor ligands; screening for molecules that restore sensitivity of tumor cells to TNF-family death receptors and so are useful therapeutic adjuncts to agents such as recombinant TRAIL and tumor vaccines; kills tumor cells | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008354-B2 | TNF-family death receptor ligand-resistant cells to one or more TNF-family death receptor ligands; screening for molecules that restore sensitivity of tumor cells to TNF-family death receptors and so are useful therapeutic adjuncts to agents such as recombinant TRAIL and tumor vaccines; kills tumor cells | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008354-B2 | TNF-family death receptor ligand-resistant cells to one or more TNF-family death receptor ligands; screening for molecules that restore sensitivity of tumor cells to TNF-family death receptors and so are useful therapeutic adjuncts to agents such as recombinant TRAIL and tumor vaccines; kills tumor cells | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2011-08-30 | — | — | US | disclosed |
| US-20080206287-A1 | Use of cyclosporin A to sensitize resistant cancer cells to death receptor ligands | REED JOHN C | 2008-08-28 | — | — | US | disclosed |
| US-20080206287-A1 | Use of cyclosporin A to sensitize resistant cancer cells to death receptor ligands | REED JOHN C | 2008-08-28 | — | — | US | disclosed |
| US-20080206287-A1 | Use of cyclosporin A to sensitize resistant cancer cells to death receptor ligands | REED JOHN C | 2008-08-28 | — | — | US | disclosed |
| US-20080166378-A1 | DEATH RECEPTOR SENSITIZING COMPOUNDS AND METHODS OF USE THEREFOR | THE BURNHAM INSTITUTE | 2008-07-10 | — | — | US | disclosed |
| US-20080166378-A1 | DEATH RECEPTOR SENSITIZING COMPOUNDS AND METHODS OF USE THEREFOR | THE BURNHAM INSTITUTE | 2008-07-10 | — | — | US | disclosed |
| US-20080166378-A1 | DEATH RECEPTOR SENSITIZING COMPOUNDS AND METHODS OF USE THEREFOR | THE BURNHAM INSTITUTE | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080206287-A1 | Use of cyclosporin A to sensitize resistant cancer cells to death receptor ligands | TNFRSF1A, TNFRSF9, CD40 | MAPT 4458/4885LMNA 2004/4885KCNJ5 4699/4885 |
| US-20080166378-A1 | DEATH RECEPTOR SENSITIZING COMPOUNDS AND METHODS OF USE THEREFOR | BAD, BAK1, MCL1 | MAPT 4634/4885LMNA 1185/4885KCNJ5 4509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.